Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC

NCT ID: NCT06202014

Last Updated: 2024-01-19

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 43 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-01-31
• Study Completion Date: 2025-12-31

Brief Summary

This is a single-arm prospective phase II clinical trial to investigate the efficacy and safety of concurrent radiotherapy with envafolimab and capecitabine in locally advanced pancreatic cancer.Eligibility patients will receive intensity-modulated radiotherapy(IMRT)or volumetric modulated arc therapy(VMAT) to pancreatic lesions,metastatic lymph nodes and high-risk lymphatic drainage areas,concurrent with and followed by envafolimab and capecitabine.

Detailed Description

This is a single-arm prospective phase II clinical trial to investigate the efficacy and safety of concurrent radiotherapy with envafolimab and capecitabine in locally advanced pancreatic cancer.Primary enrollment criteria is locally advanced non-resectable pancreatic cancer without systemic metastases other than retroperitoneal lymph nodes.Eligibility patients will receive intensity-modulated radiotherapy(IMRT)or volumetric modulated arc therapy(VMAT) to pancreatic lesions,metastatic lymph nodes and high-risk lymphatic drainage areas,concurrent with and followed by envafolimab and capecitabine.Concurrent and sequential dose of envafolimab is 200mg subcutaneous injection weekly.Capecitabine is with a concurrent and sequential dose of 500-800 mg/m2 bid po , taken orally for 2 weeks and stopped for 1 week (standard concurrent dose is 800 mg/m2 bid po , but for patients ≥70 years of age, 500 mg/m2 bid po depending on physical status ) until progression or intolerance.

Conditions

Pancreatic Cancer; Radiotherapy; Envafolimab; Capecitabine

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Concurrent Radiotherapy With Envafolimab and Capecitabine

Concurrent radiotherapy with envafolimab and capecitabine, post-adjuvant envafolimab and capecitabine for locally advanced pancreatic cancer

Group Type: EXPERIMENTAL

concurrent radiotherapy with envafolimab and capecitabine

Intervention Type: RADIATION

Eligibility patients will receive intensity-modulated radiotherapy(IMRT)or volumetric modulated arc therapy(VMAT) to pancreatic lesions,metastatic lymph nodes and high-risk lymphatic drainage areas,concurrent with and followed by envafolimab and capecitabine.Concurrent and sequential dose of envafolimab is 200mg subcutaneous injection weekly.Capecitabine is with a concurrent and sequential dose of 500-800 mg/m2 bid po , taken orally for 2 weeks and stopped for 1 week (standard concurrent dose is 800 mg/m2 bid po , but for patients ≥70 years of age, 500 mg/m2 bid po depending on physical status ) until progression or intolerance.

Interventions

concurrent radiotherapy with envafolimab and capecitabine

Eligibility patients will receive intensity-modulated radiotherapy(IMRT)or volumetric modulated arc therapy(VMAT) to pancreatic lesions,metastatic lymph nodes and high-risk lymphatic drainage areas,concurrent with and followed by envafolimab and capecitabine.Concurrent and sequential dose of envafolimab is 200mg subcutaneous injection weekly.Capecitabine is with a concurrent and sequential dose of 500-800 mg/m2 bid po , taken orally for 2 weeks and stopped for 1 week (standard concurrent dose is 800 mg/m2 bid po , but for patients ≥70 years of age, 500 mg/m2 bid po depending on physical status ) until progression or intolerance.

Intervention Type: RADIATION

Eligibility Criteria

Inclusion Criteria

1. Age: 18-90 years old.

2. Pancreatic cancer diagnosed by histology or cytology.

3. Locally or regionally advanced non-resectable pancreatic cancer without systemic metastases other than retroperitoneal lymph nodes.

4. Patients who have not received prior systemic chemotherapy or who have progressed on first-line therapy.

5. At least one measurable lesion (≥10 mm long diameter on CT scan for tumor lesions and ≥15 mm short diameter on CT scan for lymph node lesions according to RECIST 1.1 criteria).

6. ECOG score: 0-1.

7. Expected survival ≥ 3 months.

8. Normal function of major organs, meeting the following criteria:

9. Criteria for routine blood tests need to be met (no blood and blood products transfusion within 14 days):

1. ANC ≥ 1.5×10^9/L

2. PLT ≥80×10^9/L

10. Biochemical tests need to meet the following criteria:

1. TBIL<1.5 ULN

2. ALT and AST < 2.5ULN and in patients with liver metastases < 5ULN

3. Serum Cr ≤ 1.25ULN or endogenous creatinine clearance > 45 ml/min (Cockcroft-Gault formula) 11).Subjects voluntarily enrolled in this study and signed an informed consent form, were compliant and cooperated with the follow-up.

Exclusion Criteria

1. Presence of any active autoimmune disease or history of autoimmune disease in the subject.

2. Allergy to study-used medications.

3. Subjects who are on immunosuppressive, or systemic, or absorbable topical hormone therapy for immunosuppression (dose >10mg/day prednisone or other equipotent hormone) and who continue to be on it within 2 weeks prior to enrollment.

4. Class III-IV cardiac insufficiency according to NYHA criteria, or cardiac ultrasound suggesting left ventricular ejection fraction (LVEF) <50%.

5. Those with abnormal coagulation function (INR>1.5,APTT>1.5 ULN) and bleeding tendency.

6. prolonged unhealed wounds or fractures; major surgical procedures or severe traumatic injuries, fractures or ulcers within 4 weeks.

7. Subjects with congenital or acquired immune deficiency (e.g., HIV-infected individuals), or active hepatitis (Hepatitis B reference: HBV DNA test value exceeding the upper limit of normal, Hepatitis C reference: HCV viral titer or RNA test value exceeding the upper limit of normal).

8. Subject has received other prior PD-1 antibody immunotherapy or other immunotherapy targeting PD-1 or PD-L1.

9. Known existing hereditary or acquired bleeding and thrombotic tendencies (e.g., hemophiliacs, coagulation disorders, thrombocytopenia, hypersplenism, etc.) or events of arterial or venous thrombosis in the last 6 months (up to the first medication use of envafolimab ).

10. Subjects with active infection or unexplained fever >38.5 degrees Celsius during screening and prior to the first dose.

11. Patients with central nervous system metastases;

12. Subjects who have had a live bacterial vaccine or live attenuated vaccine vaccine within 30 days prior to the first dose of study treatment.

13. Subjects with previous or concurrent other malignant tumors.

14. Women who are pregnant or breastfeeding.

15. Those with a history of psychotropic substance abuse that cannot be abstained from or patients with psychiatric disorders.

16. Patients with concomitant illnesses that, in the judgment of the investigator, seriously jeopardize patient safety or interfere with the patient's ability to complete the study.

17. Those who are not suitable for inclusion in the judgment of the investigator.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

Sponsor Role: lead

Responsible Party

BO CHEN

Associate Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Bo Chen

Beijing, Beijing Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Bo Chen, MD

Role: CONTACT

cbchinese@163.com

008613240000876

Facility Contacts

Bo Chen, MD

Role: primary

chenboo@outlook.com

008613240000876

Other Identifiers

NCC4325

Identifier Type: -

Identifier Source: org_study_id